Recent Analysts’ Ratings Changes for Heron Therapeutics (HRTX)

Heron Therapeutics (NASDAQ: HRTX) has recently received a number of price target changes and ratings updates:

  • 11/12/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 11/10/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock.
  • 11/8/2017 – Heron Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
  • 11/7/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $28.00 price target on the stock.
  • 11/6/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $40.00 price target on the stock.
  • 11/2/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $31.00 price target on the stock.
  • 10/30/2017 – Heron Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set a “buy” rating and a $27.00 price target on the stock.
  • 10/26/2017 – Heron Therapeutics was given a new $31.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/20/2017 – Heron Therapeutics was given a new $31.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/6/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Noble Financial. They now have a $24.00 price target on the stock.
  • 9/27/2017 – Heron Therapeutics is now covered by analysts at Northland Securities. They set an “outperform” rating and a $40.00 price target on the stock.
  • 9/26/2017 – Heron Therapeutics is now covered by analysts at Mizuho. They set a “buy” rating and a $28.00 price target on the stock.
  • 9/25/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They wrote, “We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with HRTX in attendance.””

Heron Therapeutics, Inc. (NASDAQ HRTX) opened at $15.45 on Wednesday. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Heron Therapeutics, Inc. has a one year low of $12.21 and a one year high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities research analysts expect that Heron Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply